Skip to content

Uses of Myostaal forte tablets in Osteoarthritis of knee.

An active-controlled, randomized, comparative evaluation of Myostaal forte tablets in prevention of acute flares in Osteoarthritis of knee.

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/09/045353
Enrollment
45
Registered
2022-09-08
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M179- Osteoarthritis of knee, unspecified

Interventions

None listed

Sponsors

Dean and principal faculty of Parul institute ofAyurveda
Lead Sponsor
solumiks herbaceuticals ltd
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patients showing symptoms of sandhi Gata Vata of Janu Sandhi. 2)Diagnosed case of Idiopathic knee osteoarthritis according to clinical guidelines of American college of Rheumatology for minimum 6 months and maximum 5 years. 3)Patient having baseline knee joint pain more than 40 mm on Visual Analogue Scale (VAS) either at rest or on weight bearing activities (e.g. walking, standing, climbing staircase) during the preceding 24 hours . 4)Patients willing to give written informed consent. 5)Patients willing to follow up.

Exclusion criteria

Exclusion criteria: 1) Known case of secondary arthritis related to systemic inflammatory arthritis. 2) Known case of uncontrolled hypertension, Diabetes mellitus requiring insulin injections and chronic severe respiratory disease. 3) History of life threatening cardiovascular and /or neurological event in the past one year. 4) Pregnancy or lactation . 5) Patient with history of allergy towards any of the study medicines.

Design outcomes

Primary

MeasureTime frame
muscles strength on the basis of dynamometerTimepoint: at baseline and every 4 weeks till 24 weeks

Secondary

MeasureTime frame
chondroprotective effect on the basis of MRI Timepoint: at baseline and at 24 weeks;pain managementTimepoint: at baseline and every 4 weeks till 24 weeks

Countries

India

Contacts

Public ContactDr Vaishali Deshpande

Parul Institute of Ayurveda

dr.shaileshd@gmail.com9763104451

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026